Mason JM - Search Results

1

Intracellular screening of a peptide library to derive a potent peptide inhibitor of α-synuclein aggregation.

Cheruvara H, Allen-Baume VL, Kad NM, Mason JM. Cheruvara H, et al. Among authors: mason jm. J Biol Chem. 2015 Mar 20;290(12):7426-35. doi: 10.1074/jbc.M114.620484. Epub 2015 Jan 23. J Biol Chem. 2015. PMID: 25616660 Free PMC article.

2

Truncation, randomization, and selection: generation of a reduced length c-Jun antagonist that retains high interaction stability.

Crooks RO, Rao T, Mason JM. Crooks RO, et al. Among authors: mason jm. J Biol Chem. 2011 Aug 26;286(34):29470-9. doi: 10.1074/jbc.M111.221267. Epub 2011 Jun 22. J Biol Chem. 2011. PMID: 21697091 Free PMC article.

3

Combining intracellular selection with protein-fragment complementation to derive Aβ interacting peptides.

Acerra N, Kad NM, Mason JM. Acerra N, et al. Among authors: mason jm. Protein Eng Des Sel. 2013 Jul;26(7):463-70. doi: 10.1093/protein/gzt021. Epub 2013 May 24. Protein Eng Des Sel. 2013. PMID: 23708321 Free PMC article.

4

Retro-inversal of intracellular selected β-amyloid-interacting peptides: implications for a novel Alzheimer's disease treatment.

Acerra N, Kad NM, Griffith DA, Ott S, Crowther DC, Mason JM. Acerra N, et al. Among authors: mason jm. Biochemistry. 2014 Apr 8;53(13):2101-11. doi: 10.1021/bi5001257. Epub 2014 Mar 21. Biochemistry. 2014. PMID: 24601543

5

Intracellular selection of peptide inhibitors that target disulphide-bridged Aβ42 oligomers.

Acerra N, Kad NM, Cheruvara H, Mason JM. Acerra N, et al. Among authors: mason jm. Protein Sci. 2014 Sep;23(9):1262-74. doi: 10.1002/pro.2509. Epub 2014 Jul 2. Protein Sci. 2014. PMID: 24947815 Free PMC article.

6

Toward peptide-based inhibitors as therapies for Parkinson's disease.

Mason JM, Fairlie DP. Mason JM, et al. Future Med Chem. 2015;7(16):2103-5. doi: 10.4155/fmc.15.139. Epub 2015 Oct 29. Future Med Chem. 2015. PMID: 26510474 No abstract available.

7

Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles.

Meade RM, Fairlie DP, Mason JM. Meade RM, et al. Among authors: mason jm. Mol Neurodegener. 2019 Jul 22;14(1):29. doi: 10.1186/s13024-019-0329-1. Mol Neurodegener. 2019. PMID: 31331359 Free PMC article. Review.

8

Selective antagonism of cJun for cancer therapy.

Brennan A, Leech JT, Kad NM, Mason JM. Brennan A, et al. Among authors: mason jm. J Exp Clin Cancer Res. 2020 Sep 11;39(1):184. doi: 10.1186/s13046-020-01686-9. J Exp Clin Cancer Res. 2020. PMID: 32917236 Free PMC article. Review.

9

Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation.

Torpey JH, Meade RM, Mistry R, Mason JM, Madine J. Torpey JH, et al. Among authors: mason jm. Front Neurosci. 2020 Oct 15;14:561462. doi: 10.3389/fnins.2020.561462. eCollection 2020. Front Neurosci. 2020. PMID: 33177976 Free PMC article.

10

The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein.

Meade RM, Morris KJ, Watt KJC, Williams RJ, Mason JM. Meade RM, et al. Among authors: mason jm. J Mol Biol. 2020 Dec 4;432(24):166706. doi: 10.1016/j.jmb.2020.11.005. Epub 2020 Nov 11. J Mol Biol. 2020. PMID: 33186583

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

404 results

Search Page